Last reviewed · How we verify
Lonquex (LIPEGFILGRASTIM)
Lonquex (generic name: LIPEGFILGRASTIM) is a Recombinant protein drug developed by Sicor Biotech UAB. It is currently FDA-approved (first approved 2013) for Chemotherapy-induced neutropenia.
Lonquex, also known as lipegfilgrastim, is a granulocyte colony-stimulating factor receptor agonist used to support dose-dense chemotherapy in early breast cancer and to prevent R-CHOP-21-induced neutropenia in aggressive B cell non-Hodgkin lymphomas. It is a protein-based drug that belongs to the agonist class, acting on the granulocyte colony-stimulating factor receptor.
At a glance
| Generic name | LIPEGFILGRASTIM |
|---|---|
| Sponsor | Sicor Biotech UAB |
| Target | Granulocyte colony-stimulating factor receptor |
| Modality | Recombinant protein |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2013 |
| Annual revenue | 1200 |
Approved indications
- Chemotherapy-induced neutropenia
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2,PHASE3)
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer (PHASE1,PHASE2)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (PHASE2)
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lonquex CI brief — competitive landscape report
- Lonquex updates RSS · CI watch RSS
- Sicor Biotech UAB portfolio CI
Frequently asked questions about Lonquex
What is Lonquex?
What is Lonquex used for?
Who makes Lonquex?
What is the generic name of Lonquex?
When was Lonquex approved?
What development phase is Lonquex in?
What is Lonquex's annual revenue?
What does Lonquex target?
Related
- Target: All drugs targeting Granulocyte colony-stimulating factor receptor
- Manufacturer: Sicor Biotech UAB — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Chemotherapy-induced neutropenia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing